This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Good day and welcome to the Carew Medical Systems fourth quarter and full year 2023 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead.
spk00: Thank you, operator, and good afternoon, everyone. Earlier today, Coru Medical Systems released financial results for the fourth quarter and full year ended December 31st, 2023. A copy of the press release is available on the company's website. During this call, we will make certain forward-looking statements regarding our business plans and other matters. These comments are based on our predictions and expectations as of today. Actual events or results could differ materially due to many risks and uncertainties, including those mentioned in this associated press release and our most recent filings with the SEC. We assume no obligation to update any forward-looking statements. I encourage listeners to have our press release in front of you, which includes our financial results as well as commentary on the quarter. During the call, management will discuss certain non-GAAP financial measures in our press release and accompanying investor presentation and our filings with the SEC, each of which are posted on our website. You will find additional disclosure regarding these non-GAAP measures, including reconciliations of these measures with comparable GAAP measures in our press release and accompanying investor presentation and those filings. For the benefit of those listening to the replay, this call was held and recorded on Wednesday, March 13, 2024, at approximately 430 p.m. Eastern Time. Since then, the company may have made additional comments related to the topics discussed. And please reference the company's most recent press filing and press releases and filings with the SEC. Joining us on the call today are Linda Tharby, President and CEO of Coru Medical Systems, and Tom Adams, Coru Medical's Chief Financial Officer. Linda, please go ahead.
spk01: Thank you, Louisa. Good afternoon, everyone, and thank you for joining us today. During today's call, we will use slides to support our commentary. I will begin by walking through results and key business updates for the fourth quarter and full year 2023. Tom will then review our financials and our 2024 guidance. Following the prepared remarks, we will open the line for questions. I'm very pleased with quarter's performance in the fourth quarter. We continue to execute on our growth strategy, exceeded our gross margin expectations, and with discipline in our capital and expense management, we continue to see improvements in our quarterly cash burn. Our full year revenues ended at $28.5 million, with growth of 2% affected by a one-time non-recurring engineering services revenue in our novel therapies business. Our overall revenue growth in our core SCIG business remains strong, with U.S. performance driven by share gains and with the overall SCIG market recovering in another quarter of sequential growth. In our international business, we deliver double-digit growth year over year, primarily driven by deeper penetration in current markets and successful entry into new geographies supported by strong IG supply. In November, we announced FDA clearance of the 50 ml Hyzentra pre-filled syringes for the Coru Freedom system. Pre-filled syringes are becoming an increasingly large part of the SCIG market, and Coru is strongly positioned to capitalize on this opportunity. We believe pre-fills will be a critical growth driver for KORU and expand our penetration in our core markets. In novel therapies, we continue to build out the pipeline, having signed three additional collaborations in 23, and having started the year strong with two new in the beginning of 2024, both of which I will touch on later. From an operational perspective, I'll let Tom cover the financials with more granularity. For growth margins, we finished above 60% for the second consecutive quarter and generated positive cash flow of $700,000 in the fourth quarter. Additionally, we exceeded our 2023 ending cash balance projections, closing the year with $11.5 million. Each of these metrics serves as a testament to the steps we've taken in our operating expense management and inventory reduction initiatives. and we expect to continue the progression in operating performance in 2024 and beyond. Finally, we're initiating 2024 guidance for net revenues to range between 31.2 and 32.2 million, representing 10 to 13% growth and gross margin between 59 to 61% for the full year. Additionally, we plan to exit the year with an ending cash balance of at least 8 million and to be cash flow positive in the fourth quarter of 24, and for the full year 2025. Tom will discuss details related to the guidance and our associated assumptions later in the call. Over the last few years, we've invested in positioning CORU for growth and profitability. And as we enter 24, we expect much of that investment is behind us. I'm seeing strong momentum in our core business, our best novel therapies pipeline to date, and a focused operational discipline that is critical to our future success. 2024 will be an execution year for our team, and we believe we are poised for a return to sustained double-digit growth and profitability. Vision 26 remains our key focus moving forward, and we are positioned for a meaningful inflection point in 24 and beyond. Moving to slide four, you'll recognize the three-pillar growth strategy that is the foundation of our Vision 26 initiative. Those three being domestic SCIG penetration and growth, the broadening of our novel therapies pipeline, and geographic expansion. This strategy will continue to position CORU as a leader in the growing large volume subcutaneous drug delivery market. As it relates to our domestic core, our goal is to increase penetration into the SCIG market and further establish our leadership position. With respect to the overall SCIG market, in the fourth quarter, we saw another quarter of sequential growth and patient volume, and the market ended the year with mid to high single-digit growth. We delivered approximately 6% year-over-year revenue growth, and our end-user sales to pharmacies were up double digits, reflective of share gains. Our distributor inventories were lower at the end of Q4, and we expect to see this inventory replenished in future quarters. Increased demand for pumps drove a double-digit increase in volumes for both the fourth quarter and the full year, often a leading indicator to consumable sales. We continue to see caregivers and patients drive therapy to pre-fills due to their convenience versus traditional FCIG biotherapy. We're encouraged by these trends and believe this will benefit the commercial launch of the 50 ml Hyzentra pre-filled syringe, which began rollout in January. We also anticipate a new 510K submission for a product in the fourth quarter 2024 within core IG. Overall, we are increasingly confident in the SCIG market growth driving new patient starts and believe we are positioned for continuing share gains in our U.S. business in 2024. Turning to novel therapies, we have 15 collaborations signed to date with 19 additional open opportunities across varying indications, signing three new collaborations in 2023. I'm encouraged by our progress in early 24. In recent weeks, we've announced two new collaborations, which I will discuss later. We also have two drug collaborations progressing to phase three trials in 2024. a key milestone in the advancement to commercial launch. Looking forward, during the fourth quarter of 24, we're anticipating the submission of a 510K application to support a new novel therapy indication for use with our freedom infusion system in ambulatory infusion centers. I'm very pleased by the headway we're making within NT, by the overall strength and diversity of our pipeline, and the progress on commercialized drugs in early 25 and 26. Turning to International Core, it continues to be a great opportunity for CORU. Revenue in the fourth quarter grew 8% over Q4 22 and 10% for the full year. Strong sales growth was driven by growth in our established markets as IG supply stabilized, new indication growth in CIDP and SID, and entry into multiple new markets. As was the case in domestic core, pump and consumer volumes were another strong indicator of demand with double-digit growth. Our excitement in international is at an all-time high as we anticipate continued expansion into new regions in 2024. We also expect the completion of an electronic pump trial in the first half of the year, generating further evidence for our freedom infusion system. I'd like to shift our focus back to the IG market on slide five, and more specifically, pre-filled syringes and why we're so bullish on the opportunity this presents for core and moving forward. Pre-fills represent a major catalyst for growth within our domestic and international core markets as this delivery method is increasingly penetrating share among subcutaneous therapy patients and has the potential to increase overall sub-Q penetration. Pre-filled syringe patients grew 24.5% in the fourth quarter and increased overall penetration to 14% as the fastest growing part of the overall IG market. Overall, we see a number of factors that will continue to drive growth. First, patient preference was 78% of patients preferring the use of pre-fill with the Freedom Pump versus vial administration. Additionally, the 50 mL dose clearance represents two-thirds of the pre-filled market And combined with the earlier 20 ml launch provides CORA with a broad portfolio to fulfill all patient needs. We've been focused with our pharmaceutical partners in driving a clinical practice change to pre-fills, driving even greater uptake in usage due to the increased convenience. We expect increased penetration with CIDP patients who require much higher doses and twice weekly therapy. We are excited by our position and potential for pre-bills to drive growth and higher penetration, reaching levels of 20 to 25% for foliar penetration in 24 and 50% by the end of year 25. Turning to slide six, we are very pleased to announce that we will be presenting new data at the 2024 National Home Infusion Association Conference later this month. This study focused on patient adherence to the Freedom system and collected data from over 11,000 patients with primary immune deficiencies who self-administered their SCIG therapy using the Coru Freedom pump. This retrospective study conducted over a four and a half year period revealed an impressive adherence rate of 97% to the prescribed treatment protocol. To provide context, adherence rates for other chronic conditions such as high blood pressure, cholesterol, arthritis, and diabetes range somewhere from 62% to 87%. This comparison highlights the exceptional performance of the CoroFreedom pump system in promoting treatment consistency and improving patient satisfaction. Overall, these findings underscore the effectiveness of the CoroFreedom pump system in facilitating strong adherence to SCIG therapy among PID patients, leading to improved treatment outcomes and patient satisfaction. We look forward to sharing these results at the upcoming NHIA conference with our prospective new customers. Turning to our novel therapies pipeline, we have the strongest pipeline we have reported to date. In 2023, we added three new collaborations to our pipeline. bringing our total collaborations to 15, and we are pursuing another 19 open opportunities. This NT pipeline translates to a total addressable market of approximately 2.7 billion through the treatment of over 1.6 million people globally. 2024 is already off to a strong start, and I want to highlight the two recent collaborations we've announced, the first being the initiation of a feasibility study with Coru's system, on an already commercialized rare disease therapy. And the second, a clinical supply agreement to support a pre-commercial unnamed SCIG drug entering its phase three trials. Novel therapies is a key piece to CORA's growth strategy as it creates opportunities for future drug indications that can grow our CORA business significantly once commercialized. We also anticipate entry in Japan with increasing SCIG approvals. Our team is focused on late-stage drug opportunities with potential for commercialization over the next three years in both the home and ambulatory infusion settings. The near-term targets are those collaborations we expect to go live with KORU, totaling six new potential entries by the end of 26 are highlighted in the lighter green on the far right of the slide. I'm encouraged by the incremental advancement in our funnel and truly believe that novel therapies will be transformational to increasing our leadership position as a global leader in large volume drug delivery and driving our commercial potential in our core business. In 2023, we've laid the foundation for a strong 24 and are on a path to continue double digit growth with a clear line of sight to profitability in 25. I'm excited by our current momentum as we remain focused on the execution of our Vision 26 strategy and positioning Quora for continued growth and profitability. I will now turn it over to Tom to review our financials.
spk02: Thank you, Linda, and good afternoon, everyone. We closed the quarter with a total net revenue of $7.2 million, which was below the prior year by 2%. We were pleased with our quarterly performance in our domestic and international core business. For the quarter, we reported domestic core revenues of 5.6 million, reflecting 5% year-over-year growth. This growth was driven by share gains in new accounts, double-digit growth in infusion pump sales, and an overall healthy FCIG market. In addition, and as Linda pointed out, the end-user sales, which are indicative of our demand, were very strong during the quarter, which we expect to be reflected in future replenishments of distributor inventory. The international core business increased 8% year-over-year with revenues of $1.3 million driven by improved IG supply across Europe, expansion into new geographies, and double-digit growth in pump and consumable volumes. Our novel therapies business reported revenues of $200,000 or a 62% decrease driven by a large revenue milestone we completed for non-recurring engineering services in 2022. Moving to slide 9, for the full year 2023, total net revenues were $28.5 million, increasing 2% over the prior year. Domestic core sales totaled $22.4 million, which was a 6% year-over-year increase, driven by growth in pumps and consumables attributed to share gains in national and regional accounts. 2023 also marked a record year in infusion pump unit sales. With this growth, we expect our consumables revenue to follow as our pumps make it into the hands of nurses and patients. International core revenues were 4.6 million, representing a 10% increase compared to the prior year. Growth internationally was driven by increased sales and established markets, as well as expansion into new geographies. Novel therapies revenues were 1.5 million, reflecting a decrease of 41% in the year. The decline was a result of higher NRE recognized and increased clinical trial orders from the prior year. We carry revenue potential from a number of pipeline opportunities into 2024. Moving on to gross margins in slide 10. For the fourth quarter, we delivered GAAP gross margins of 60.3, which was a 470 basis point improvement over the prior year. Our non-GAAP gross margin for the quarter was 63.1%. The non gap gross margin allowed for a one time inventory Justin related to the product is continuation that had no impact on that. Margin improvements in the quarter were driven by increases in manufacturing efficiencies related to a site closure outsourcing of consumer manufacturing and favorable changes in product. For the full year 2023 gap gross margin was 58.6 a 350 basis point improvement over the full year 2022. which is driven primarily by our outsourcing efforts and improvements in manufacturing productivity and product next non gap growth margin for the year was 59.6 which allowed again for a one time adjustment for a practice continuation. I'm glad 11 at the end of the 4th quarter we finished the year with a cash balance of 11.5 million representative of a $700,000 cash game for the quarter. Our Q4 cash improvement was driven by lower losses in the second half of 2023 driven by improved gross margin and discipline operating expense control. Additionally, there was an increase in capex in the quarter on tooling related to the development of our next generation products. Offsetting these uses of cash, we achieved significant working capital improvement led by the completion of our inventory reduction plan, collection of earned retention credits, and typical year-end accruals. During the fourth quarter, we also recorded a non-cash valuation allowance against our deferred tax set of $6 million. As we review our cash usage by quarter, we improved directionally throughout 2023. The first quarter had a higher level of spending as a result of one-time investments in CapEx and onboarding of new hires, which tapered off significantly throughout the year. Moving into 2024, we expect quarterly cash usage to remain consistent to follow a similar cadence, but at a significantly lower burn rate. As Linda noted earlier, given our improved operating leverage and our plan reduced cash usage, we expect to be cash flow positive in the fourth quarter of 2024 and for the full year 2025. Net loss for the 4th quarter of 2023 was 7.5 million or 16 or negative 16 cents per diluted share compared to a net loss of 2 million or negative 4 cents per diluted share for the same period of 2022. Net loss for the full year of 2023 was 13.7 million or negative 30 cents per diluted share compared to a net loss of 8.7 or negative 19 cents per diluted share for the same period of 22. Our net loss in EPS for both the quarter and the full year included a tax valuation allowance of $6 million. Adjusted EBITDA for the quarter was negative $1 million or negative $0.02 for diluted share versus negative $1.6 million or negative $0.04 in the prior year. And adjusted EBITDA for the full year was $6 million negative or negative $0.13 for diluted share versus negative $0.061. 0.1 million or negative 14 cents in the prior year. Moving on to slide 13, we are setting our revenue guidance for the full year of 2024 between 31.2 and 32.2 million, representing roughly a 10% to 13% growth. Key drivers behind these estimates include, one, core SCIG drug market growth in the mid to high single digits, the second, adding three new collaborations to the novel therapies pipeline and a third pre-filled syringe penetration of approximately 20% to 25% of the overall SCIG market. We expect gross margins to range between 59% to 61%, primarily as a result of geographic expansion into lower ASP markets, supply chain inflationary pressure, and startup costs for a new production line in the second half of the year. Finally, we expect our 2024 ending cash balance to be greater than $8 million, implying a significant cash burden decrease from prior years. Assumptions to this guidance are driven by managing operating expenses of approximately $23.5 million to $24 million, exclusive of stock compensation expenses. We also are expecting cash flow to break even in Q4 and to be cash flow positive for the full year of 2025. Finally, all our cash guidance I just mentioned is exclusive of our new $10 million credit facility. Our new credit facility consists of a $5 million line of credit and a $5 million term loan with HSBC USA, with which we have established a new commercial banking relationship. We are pleased to have this new reserve available to us for strategic growth capital opportunities. I will now turn the call back to Linda for closing comments.
spk01: Thanks, Tom. In the last several years, we've invested in our R&D pipeline and new product innovation to drive increased market penetration, share gains, and accelerated growth. As we discussed, we have already received FDA approval for the 50ml Hyzentra on our Freedom60 platform, which will aid in expanding our customer base. In the near term, we expect a 510k submission for our new infusion set, which will provide a more comfortable and convenient experience, and our next generation infusion pump for IG. In the longer term, we expect a pump platform for novel therapies that will be customizable to the pharmaceutical partner's needs. We are very excited to bring each of these products to market as we look to assist both customers and pharmaceutical drug manufacturers in providing the best subcutaneous infusion experience to patients. In closing, we have a few key milestones that I would like to highlight for 2024 within our financial and operational performance. We anticipate returning to double-digit net revenue growth versus full year 23. We look to accelerate our U.S. core share gains through increased penetration of 50 ml pre-filled syringes while also continuing our international expansion in current and new markets. On the novel therapies front, we expect to enter three new collaborations in the year, focusing on late-stage candidates that have a higher probability of reaching commercialization prior to 2026. We are projecting the submission of two 510 s, one for a new product and the other for a new drug indication on the Freedom platform. Finally, it is our commitment to break even cash flows in Q4 of 24 and cash flow positive for full year 2025. Each of these milestones are strong indicators of the progress we are making toward CORU's overarching Vision 26 goals. Overall, I am pleased with our fourth quarter and 23 results and am strongly encouraged by our strategic outlook across all of our businesses heading into 24. We continue to strive to evolve our company to a leader in drug delivery in both the clinic and at-home setting to the convenience of our products as demonstrated by our long-term plan and milestones for the year. In closing, I would like to thank the entire CORU team for their continued passion and dedication. Operator, I will now turn the call over to you for Q&A.
spk03: I'll begin the question and answer session. To ask a question, you may press star then 1 on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, Please press star, then two. Our first question comes from Frank Tekinen with Lake Street Capital. Please go ahead.
spk06: Great. Thanks for taking the questions. Congrats on all the progress and a strong start to the year. I was hoping to start with one on guidance. I saw and heard the comments around some of your assumptions about SSI. CIG market growth, novel therapies, pre-filled syringe penetration. I was hoping you could kind of break it down by line item, maybe domestic, international, and novel therapies. How should we think about the growth profile, the guide for 2024? And then to add on to that, how should we think about the contribution from the Hyzentra 50 ML?
spk01: Okay. I think I got it all. I'll start and then turn it over to Tom. First, yes, our overall performance, 31.2 to 32.2 million expectation for 2024. We do not guide by business, but let me give you a couple of the key points. In our U.S. business, we would anticipate the market overall to grow somewhere in that 7.5% range, and we expect our performance to be a couple of points above that. driven by share gain, primarily pre-filled syringe and increasing pre-filled penetration, particularly in the CIDP patient base. Our international performance, you can expect, so that in the U.S. business is a nice acceleration from where we ended this year. On our overall performance, International business, we would expect the overall year in our international business to be up appreciably from where we ended this year. Probably think about a growth trajectory somewhere in the 15 to 20% range. And then finally, for our novel therapies business, we would say overall, you can expect that business somewhere between the $1.5 and $2 million mark overall in the year.
spk06: Okay, perfect. That's helpful. And then maybe just as a follow-up to one of the earlier PRs from this week on the ambulatory infusion setting, maybe talk about that specific opportunity and extend that into kind of how you think about the ambulatory infusion market as an overall opportunity going forward.
spk01: Yeah, so ambulatory infusion centers, just to set the stage there, are a market that exists between the hospital and the home setting. where drugs, there have been eight new drugs launched in the last three years, which require administration by a healthcare professional in that setting. As I noted in our investor day, that was a key area of progress for us because the drugs are already commercialized. So I'm very excited that we were able to finalize this deal, announce it in the first quarter, for a drug asset that is already commercialized in those settings. On top of that, that asset will use a customized CORU platform, and we anticipate that we will file a 510 for that in the U.S. followed by ex-U.S. geographies. We continue to see the infusion centers as being an opportunity for incremental growth. a new area that represents near-term commercial potential and just overall very, very excited about the opportunity. We have several more that we are focused on in our pipeline and hopefully more to report in the coming quarters.
spk05: Perfect. Okay.
spk06: I'll stop there. I'll let someone else hop in. Thanks for taking the questions.
spk03: The next question comes from Alex Nowak with Craig Hallam Capital. Please go ahead.
spk08: Okay, great. Good afternoon, everyone. Maybe to follow up around the core business for Kuru, we've spoken a lot about the 50-milliliter pre-filled launch, but I'm curious. I've been seeing a lot of TV ads on CIDP recently. So are we seeing a bigger uptake in that part of the market than maybe we would have thought? What are your thoughts there?
spk01: Yeah, so... Currently, of our total user base, CIDP would account for about 10% of our total user base and is only today about 10% penetrated into SCIG therapy. So this is a major focus of all of the SCIG players to convert them from IV to SCIG therapy. With the advancement of pre-fills, because of the convenience, You know, about 80% of patients prefer these, and the very large doses that they require, this is a significant opportunity to take that 10% penetration level and grow it to levels that are similar. For example, in PID, we would see about 50% penetration in that patient base. So overall, CIDP in the coming years is a significant area of growth. And speaking to our customers, they are reporting daily patients coming in, asking and being converted with doc prescriptions to go from IV to sub-Q therapy. So very excited overall for the opportunity.
spk08: Okay, got it. So certainly the pre-filled, the 50 milliliter pre-filled is going to be very helpful, whether it be PIDD or CIDP. So that makes total sense. What do you need for Kuru to get ready to help Decata with their launch in Japan?
spk01: An approval by the regulatory bodies. We've been waiting for this one. Yes. So as you know, we submitted that file sometime. We continue to progress commercial discussions with all of the pharmaceutical partners for that entry. So we are excited. And it's just a regulatory approval is what we need.
spk08: Okay, got it. And then a clarification and then just one more question. Three new collaborations was mentioned in the prepared remarks a couple times. Do you mean three new collaborations in total for 2024 or three more than what we've already been, that's already been announced so far up until now?
spk01: Yeah, that is three in total, which would include the two we've already announced. And what I would say is we have a lot of work to do on the 15 that are already in the pipeline. You know, these generally start with feasibility. Many of them involve innovation agreements. They then go into clinical trial approvals. So a lot of work to do in there. But three is the number. We obviously hope to exceed that number. But three is what we're counting on for our guidance right now. So obviously excited that we have two of those out of the way a couple of months in here.
spk08: Yep. Makes total sense. And then just lastly, 2024, it should be a good year and should be building up into, I think, a very strong 2025. If you put together the core IG business, the K to Japan launch, the 50 milliliter pre-fill, the rare disease launch, what is a realistic view on what the longer-term growth can start to look like for Kuro? Is the growth that provided in the 2024 number the longer-term growth, or could we get above that?
spk01: I would say thank you, because you just named off, you know, all of the key areas that we're looking at, right? And I would say, in addition to that, continued strength in the IG market, you know, our share gains here in the U.S., the NT progression and successful commercial entries, all of which I laid out today, six shots on goal, you know, coming into 25 and 26, and then incremental expansion internationally. that's become a real driver for us. So overall, you know, we believe our numbers can be 20, 25 plus percent growth is what we're looking at for 25 and a little bit stronger. Sorry, the only thing I missed was new products, obviously. Those new products launching add to that share grain perspective.
spk08: All right, excellent. Thanks for the update.
spk01: Thank you.
spk03: The next question comes from Caitlin Cronin with Canaccord Genuity. Please go ahead.
spk04: Hi, everyone. Thanks for taking the questions. Just to start off with 2024 guidance, what does that really imply from a quarterly cadence perspective for both revenue and gross margin?
spk01: Maybe I'll let Tom handle that question.
spk02: Sure. So we typically don't guide by quarter, Caitlin, but you can expect increasing revenues throughout the quarter. And I would say that, you know, on the novel therapy side, as you know, that business is rather lumpy and revenue is reflective as work is performed and milestones are completed. But I would say on the core side, that's more of an increasing type of revenue that you can model out. And then in terms of gross margin, Yeah, I mean, you know, gross margin, there's three things that are impacting the year. And the first thing is we are launching new products and we're ramping up our facilities in the second half of the year. And when you do that, you typically have some inefficiencies within manufacturing as you store up a new facility. Again, that's the second half of the year. And then I would say also with that, we are growing internationally. And those ASPs are generally at a lower ASP than what you'd see in the U.S. market. So I would say all in all, you can mile out a gross margin that would be pretty consistent with maybe a little bit of a drop in the Q3 timeline and then a bounce back up in Q4.
spk01: Caitlin, maybe the only additional thing that I would add to what Tom had to say is You would expect that our quarterly revenues would follow prior year patterns. We typically tend to have a stronger Q1, generally driven by new insurance, so where people switch providers and we'll get new pumps and or new consumables with that provider.
spk04: Got it. Okay. And then just on gross margin again, are the supply chain inflationary pressures that you noted in the press release, are these new or are these just pressures that have been going on for some time?
spk02: I'd say a combination. As you know, inflation has not gone away. It's still out there. And so we still anticipate some price and pressures from some of our vendors. And also, we just completed our budget. And typically, a lot of our new contracts, they renew in the first quarter. So There are some pricing increases from those renewals that we're working with.
spk05: Okay. Thank you. Thank you. Operator, further questions?
spk03: Again, if you have a question, please press star and then one. Our next question comes from Jason Bednar with Piper Sandler.
spk07: Hey, good afternoon. Thanks for taking the questions here. I want to maybe follow up on some items that have been touched on, but just hopefully unpack a few things a bit more. You know, Caitlin's question there around cadence, you know, maybe if I string that together with a prior question around, you know, acceleration to 25, I mean, it would seem like your comps, first half versus second half, you should have an acceleration, you know, first half, second half in the growth rate this year. So that we're not looking at such a large step up in the growth rate heading into 25. So I guess, you know, is that the right way to think about it on that side? And then, you know, Tom, on your gross margin points there, again, it was Caitlin's question, the supply chain costs picking a little bit higher. You know, is this, you know, do we need to have like a little bit of downshift in how we were thinking about gross margins in your 26 plan? Are those incremental to that 26 plan or are those contemplated within there? Just trying to understand if anything's changed.
spk02: Yeah, so let me start with the gross margin since we were just on that topic. I would say that, you know, there are some one-time gross margin impacts. Again, as I mentioned, the Starting up of a new production line, it definitely creates inefficiencies when you do that as you're trading on bonds from one site to the other. So that's one piece that I would imagine would resolve itself in future periods after this year. And then just in terms of your question around the revenue growth, sure, we will see increasing and we will see You know, as we see the pre-filled syringes uptick over the quarters, we will see upticks. We also will see, you know, we are expecting approval for the Japanese market. And there's some other drivers that are included in the back half of the year, which will help our revenue.
spk01: And maybe the only other thing I would add to that is given the revenues we carried in on novel therapies this year, you can expect a more even cadence in our novel therapies revenues throughout the year. They will not be as back-end loaded as what we anticipated last year because of what we carried into this year.
spk05: Okay. All right. Got it.
spk07: I want to shift gears. I don't think it's been touched on yet. Apologies if I missed it. But you mentioned in your PR today an assessment report from your European notified body. What does this mean for your European business? Does it affect at all your ability to sell in that market or get products approved in that market? When do you expect to hear an update from BSI? Anything additional there? Because, again, it could be important. It's just hard to tell if it is or not.
spk01: Yeah, no, thank you for the question, Jason. So let me start by saying that we are currently certified for sale in the EU, so no issue there. Every year you go through an annual recertification process. They were in, BSI is our auditor, they were in in February, to which we had zero non-conformances. So that's awesome in our manufacturing and quality systems. We had one open technical file on one product. And they recommended we had submitted our response to that open file to BSI and we had been informed by them that they would come back with questions or that the file was closed. That was in March of 2023. So, we were quite surprised when we got this report last week saying that they were not recommending our recertification. due to this one product and open technical file. We have launched an appeal. As of last evening, they came back and acknowledged that they have received that appeal, and we expect to resolve this in cooperation with them in the coming months. We expect little to no interruption in our sales in the European market. Our products continue to remain certified, marketed, and sold in the EU.
spk07: Okay. All right. That's helpful. I mean, Linda, again, I don't want to throw out like the worst case, but just so we're prepared. I mean, what's the best case is we come back and there's like no impact whatsoever or it's de minimis or what's worst case here just so we can prepare accordingly?
spk01: Yeah. Great question. So, best case is that there is no interruption at all. We are, while we work through this situation, any product that we have in the market, we can continue to sell. So that's best case. And worst case, what I would say is, worst case would be that they say we are not... They stand by their original and do not accept our appeal. Again, I feel that's highly unlikely given what we've sent them on their prior communication to us, which is that's why we're appealing. But if they decide to uphold that, then I would say it would take us several months to resolve. We feel we can resolve it on our end in several months. We feel it may take them some time to review the file. So you take all of those things into impact, I would say the worst case scenario would be several months of non-supply. I would cap that at probably three months in Europe of non-supply of products.
spk05: Okay. All right. Very helpful. Thanks so much.
spk03: This concludes our question and answer session. I would like to turn the conference back over to Linda for any closing remarks.
spk01: In closing, I just want to say thank you to the KORU team and to all of our investors for the continued progress in 2023, and we look forward to a great year in 2024.
spk05: Thank you. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer